|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's range||171.06 - 179.85|
|52-week range||115.61 - 464.85|
|Beta (5Y monthly)||1.60|
|PE ratio (TTM)||5.34|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
MRNA vs. TECH: Which Stock Is the Better Value Option?